Literature DB >> 2645052

Immunohistochemical phenotyping of human solid tumors with monoclonal antibodies in devising biotherapeutic strategies.

S K Liao1, C Meranda, B P Avner, T Romano, S Husseini, B Kimbro, R K Oldham.   

Abstract

A panel of 14 monoclonal antibodies (MoAbs) (4 raised against breast cancer, 6 against colon cancer and 4 against melanoma) were used to phenotype frozen sections of tumor biopsies obtained from 110 patients, by avidin-biotin-peroxidase complex techniques. We observed heterogeneity of antigen expression among the multiple metastatic lesions of single patients, as well as among tumor lesions from different patients with similar tumor histotypes. A wide range of cross-reactivity of anti-(breast-carcinoma) and anti-(colon-carcinoma) MoAbs with other carcinoma histotypes and limited reactivity with melanoma and sarcoma was detected. Some of our anti-melanoma MoAbs were also found to cross-react with selected carcinomas. Nine of the 14 MoAbs most reactive with carcinomas of diverse histotypes have been identified. A mixture or 'cocktail' of different MoAbs could be selected for each individual patient in order to achieve binding of MoAbs with most, if not 100% of tumor cells. This study illustrates the approach that we have taken to individualize the cocktail of MoAbs for the development of patient-specific therapeutic immunoconjugates.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2645052     DOI: 10.1007/bf00199106

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  43 in total

1.  Experience with the Oxford tumour marker (Ca1) in serous fluids.

Authors:  G Pallesen; F L Jepsen; J Hastrup; A Ipsen; N Hvidberg
Journal:  Lancet       Date:  1983-06-11       Impact factor: 79.321

2.  Antigen expression in human melanoma cells in relation to growth conditions and cell-cycle distribution.

Authors:  T Lindmo; C Davies; E K Rofstad; O Fodstad; A Sundan
Journal:  Int J Cancer       Date:  1984-02-15       Impact factor: 7.396

3.  Modulation of human acute lymphoblastic leukemia antigen induced by monoclonal antibody in vitro.

Authors:  J Ritz; J M Pesando; J Notis-McConarty; S F Schlossman
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

4.  Monoclonal antibody recognizing human melanoma-carcinoma cross-reacting oncofetal antigen epitopically associated with carcinoembryonic antigen.

Authors:  S K Liao; P C Kwong; B J Clarke; P B Dent; E D Ryan; M J Khosravi; S Laferte; M J Krantz
Journal:  J Natl Cancer Inst       Date:  1985-05       Impact factor: 13.506

5.  Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, breast, and gastrointestinal tumours.

Authors:  A A Epenetos; K E Britton; S Mather; J Shepherd; M Granowska; J Taylor-Papadimitriou; C C Nimmon; H Durbin; L R Hawkins; J S Malpas; W F Bodmer
Journal:  Lancet       Date:  1982-11-06       Impact factor: 79.321

6.  Immunohistochemical detection of antigen in human primary and metastatic melanomas by the monoclonal antibody 140.240 and its possible prognostic significance.

Authors:  P G Natali; J T Roberts; F Difilippo; A Bigotti; P B Dent; S Ferrone; S K Liao
Journal:  Cancer       Date:  1987-01-01       Impact factor: 6.860

7.  Human melanoma-specific oncofetal antigen defined by a mouse monoclonal antibody.

Authors:  S K Liao; B J Clarke; M Khosravi; P C Kwong; A Brickenden; P B Dent
Journal:  Int J Cancer       Date:  1982-11-15       Impact factor: 7.396

8.  Clonal variation in expression of a human melanoma antigen defined by a monoclonal antibody.

Authors:  M Y Yeh; I Hellström; K E Hellström
Journal:  J Immunol       Date:  1981-04       Impact factor: 5.422

9.  Therapeutic murine monoclonal antibodies developed for individual cancer patients.

Authors:  B P Avner; S K Liao; B Avner; K DeCell; R K Oldham
Journal:  J Biol Response Mod       Date:  1989-02

Review 10.  Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies.

Authors:  P A Edwards
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

View more
  5 in total

1.  Cultured cell lines from human breast cancer biopsies and xenografts.

Authors:  W M Lewko; R Vaghmar; D Hubbard; M Moore; Y J He; L Chang; S Husseini; K Wallwork; G B Thurman; R K Oldham
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

2.  Human tumor and normal tissue reactivity of the anti-(breast cancer) monoclonal antibody BA-Br-3 and its similarity to the anti-(epithelial membrane antigen) monoclonal antibody E29.

Authors:  S K Liao; R E Flahart; B Kimbro; L Horton; R K Oldham; J Hilgers; R van der Gaag
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

Review 3.  Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance.

Authors:  Greg M Thurber; Michael M Schmidt; K Dane Wittrup
Journal:  Adv Drug Deliv Rev       Date:  2008-04-24       Impact factor: 15.470

4.  Cultured breast cystosarcoma phylloides cells and applications to patient therapy.

Authors:  W M Lewko; R Vaghmar; J R Maleckar; S Husseini; C A Montgomery; G B Thurman; R K Oldham
Journal:  Breast Cancer Res Treat       Date:  1990-12       Impact factor: 4.872

5.  Molecular events associated with epithelial to mesenchymal transition of nasopharyngeal carcinoma cells in the absence of Epstein-Barr virus genome.

Authors:  Jung-Chung Lin; Shuen-Kuei Liao; En-Huei Lee; Man-Shan Hung; Yiyang Sayion; Hung-Chang Chen; Chen-Chen Kang; Liang-Sheng Huang; Jaw-Ming Cherng
Journal:  J Biomed Sci       Date:  2009-11-24       Impact factor: 8.410

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.